How Blood Biomarkers Help Assess Ovarian Cyst Risks
Learn how blood biomarkers help assess ovarian cyst risks. Understand CA-125, HE4, and other key markers used in UK health screening for ovarian health.
Ovarian cysts are remarkably common — most women of reproductive age will develop at least one during their lifetime. While the majority of ovarian cysts are benign and resolve without intervention, some may require closer monitoring to assess whether they pose any significant health risk. Blood biomarkers offer an objective, evidence-based way to evaluate the nature of ovarian cysts, providing healthcare professionals with measurable data that complements imaging and clinical examination.
At Health Screening Clinic, our nurse-led team in London provides private blood testing and reporting to support women who wish to take a proactive approach to their ovarian health. In this article, we explain how key blood biomarkers are used to assess ovarian cyst risks, what each marker measures, and how to make sense of your results.
What Are Blood Biomarkers for Ovarian Health?
Blood biomarkers are measurable substances found in the blood that reflect underlying physiological or pathological processes. In the context of ovarian health, certain biomarkers can help evaluate the nature of cysts — whether they are likely to be functional, benign, or warrant further investigation — and assess overall risk levels.
It is important to understand that biomarkers are not definitive diagnostic tools on their own. They are most useful when interpreted alongside imaging results, clinical history, and symptoms. A biomarker reading outside the normal reference range does not automatically indicate a serious condition, just as a result within range does not guarantee the absence of a concern.
Practical Insight: A single biomarker result is rarely conclusive on its own. The clinical value of blood biomarkers increases significantly when they are assessed in combination and interpreted within the broader context of your health profile.
Key Blood Biomarkers Used to Assess Ovarian Cyst Risks
Several biomarkers are commonly used in clinical practice and private health screening to help evaluate ovarian cysts. Below, we outline the most widely recognised markers, what they measure, and their relevance.
CA-125 (Cancer Antigen 125)
CA-125 is a glycoprotein found on the surface of ovarian cells and is one of the most well-known biomarkers associated with ovarian health. Elevated CA-125 levels can sometimes be observed in women with certain ovarian cysts, particularly endometriomas and, less commonly, in association with ovarian malignancies.
However, CA-125 is not specific to ovarian cysts alone. Levels can also be elevated by a range of benign conditions, including:
- Endometriosis
- Uterine fibroids
- Pelvic inflammatory disease (PID)
- Menstruation
- Pregnancy
- Liver disease
Practical Insight: An elevated CA-125 level does not necessarily indicate a serious condition. Many benign gynaecological and non-gynaecological conditions can cause CA-125 to rise. Context matters — always discuss your results with a qualified healthcare professional.
HE4 (Human Epididymis Protein 4)
HE4 is a newer biomarker that has gained recognition for its higher specificity in the assessment of ovarian cyst risks. Unlike CA-125, HE4 is less likely to be elevated by common benign conditions such as endometriosis or menstruation, making it a particularly useful complementary marker.
When used alongside CA-125, HE4 can help reduce false-positive results and provide a more nuanced picture of ovarian health. For a detailed comparison of these two biomarkers, see our article on CA-125 vs. HE4: Why a Combined Approach May Be More Reliable.
ROMA Score (Risk of Ovarian Malignancy Algorithm)
The ROMA score is a validated algorithm that combines CA-125 levels, HE4 levels, and the patient’s menopausal status to generate a risk stratification score. This score categorises individuals into lower or higher risk groups, which can help guide further clinical decision-making.
The ROMA score is particularly valuable because it accounts for the known differences in biomarker behaviour between premenopausal and postmenopausal women, offering a more personalised assessment than either marker alone.
Additional Supporting Markers
Depending on the clinical scenario, additional blood markers may be requested to build a more complete picture:
- Full Blood Count (FBC) — to assess general health status and identify signs of infection or inflammation
- Lactate Dehydrogenase (LDH) — sometimes elevated in certain types of ovarian germ cell tumours
- Alpha-Fetoprotein (AFP) — a marker occasionally used in the assessment of specific ovarian tumour types
- Human Chorionic Gonadotropin (hCG) — to rule out pregnancy-related causes of cyst formation or elevated biomarkers
- Hormonal markers (FSH, LH, oestradiol) — to assess overall hormonal balance and ovarian function
Comparison of Key Ovarian Cyst Biomarkers
The table below provides a summary of the most commonly used blood biomarkers for assessing ovarian cyst risks, including what each measures and its relative specificity.
| Biomarker | What It Measures | Commonly Elevated In | Specificity for Ovarian Cysts |
|---|---|---|---|
| CA-125 | Glycoprotein on ovarian cell surfaces | Endometriosis, fibroids, PID, menstruation, pregnancy | Moderate — elevated by many benign conditions |
| HE4 | Protease inhibitor protein | Certain ovarian epithelial changes | Higher — less affected by benign causes |
| ROMA Score | Combined algorithm (CA-125 + HE4 + menopausal status) | Used for risk stratification rather than direct measurement | High — personalised risk assessment |
| LDH | Enzyme involved in cellular metabolism | Germ cell tumours, tissue damage, infection | Low — non-specific but supportive |
| AFP | Protein associated with foetal development | Certain germ cell and yolk sac tumours | Low — used for specific tumour types only |
Practical Insight: No single biomarker provides a complete answer. The combination of CA-125, HE4, and supporting markers — interpreted alongside imaging and clinical context — is far more meaningful than any individual result in isolation.
Who Should Consider Ovarian Cyst Blood Testing?
Ovarian cyst blood testing may be worth considering if you:
- Have been diagnosed with an ovarian cyst on ultrasound and want additional information about its nature
- Are experiencing persistent pelvic pain, bloating, or discomfort that has not yet been fully explained
- Have a family history of ovarian or breast conditions, particularly involving BRCA1 or BRCA2 gene variations
- Are postmenopausal and have been found to have a new ovarian cyst
- Wish to establish a baseline set of ovarian health biomarkers as part of a proactive approach to wellbeing
- Have previously had elevated biomarker results and want to monitor changes over time
- Are seeking a second opinion or additional data to support a clinical discussion
Private blood testing allows women to access ovarian health biomarkers without the need for a GP referral, often with faster turnaround times than NHS pathways. For broader context on gynaecological screening options, explore our guide on cervical cancer screening vs ovarian screening differences.
Practical Insight: Women in London seeking private blood testing for ovarian cyst assessment value the convenience, speed, and breadth of markers available through private clinics — particularly when NHS waiting times for specialist referrals can be lengthy.
How Often Should You Test Ovarian Biomarkers?
The frequency of ovarian biomarker testing depends on your individual circumstances, risk factors, and clinical history. General guidance includes:
- Baseline testing — establishing your personal baseline levels is a valuable first step, particularly if you have known risk factors or have been diagnosed with an ovarian cyst
- Periodic monitoring — for women with no specific concerns, annual or biannual testing as part of a broader women’s health screening programme may be appropriate
- Follow-up testing — if previous results were borderline or elevated, repeat testing at intervals recommended by a healthcare professional can help track trends and inform ongoing management
For more information on women’s health blood tests and screening options, read our article on why HE4 may offer improved specificity compared to CA-125 in premenopausal women.
What Do Your Results Mean?
Normal Range Results
Results within the normal reference range generally suggest that no significant elevation has been detected at the time of testing. This is reassuring, although it does not guarantee the absence of all ovarian concerns — some conditions may not produce measurable biomarker changes in their early stages.
Borderline or Mildly Elevated Results
Borderline or mildly elevated results can sometimes reflect benign conditions, hormonal fluctuations, menstruation, or other non-concerning factors. In many cases, a healthcare professional may recommend repeat testing after a defined interval to assess whether levels return to normal or continue to change.
Significantly Elevated Results
Significantly elevated results may indicate that further investigation is advisable. This could involve additional imaging, a specialist referral, or further blood testing. It is important to remember that an elevated biomarker does not constitute a diagnosis — it is a signal that warrants professional review and discussion.
Practical Insight: Blood biomarker results are one piece of a larger puzzle. They are most meaningful when interpreted alongside imaging, clinical history, symptoms, and expert guidance. Always share your results with a qualified healthcare professional for personalised advice.
Blood Biomarker Testing in London: NHS and Private Options
Women in London have access to both NHS and private pathways for ovarian biomarker testing. The table below highlights some of the key differences to help you make an informed decision about your screening options.
| Feature | NHS Pathway | Private Screening |
|---|---|---|
| Access | GP referral typically required | No referral needed — book directly |
| Waiting Times | Variable — can be several weeks | Appointments often available within days |
| Scope of Testing | Usually limited to CA-125 initially | CA-125, HE4, ROMA, and additional markers available |
| Results Turnaround | Can take 1–2 weeks or longer | Typically within a few working days |
| Cost | Free at point of use | Fee applies — varies by panel selected |
| Follow-Up | GP or specialist review | Results shared with GP if requested; further testing available |
Practical Insight: Many women choose private testing to establish baseline data or to access a broader panel of markers than may be offered through standard NHS pathways. Private results can also be shared with your GP to support ongoing clinical discussions.
Frequently Asked Questions
What blood biomarkers are used to assess ovarian cyst risks?
The most commonly used biomarkers include CA-125, HE4, and the ROMA score. Additional markers such as LDH, AFP, hCG, and hormonal markers (FSH, LH, oestradiol) may also be used depending on the clinical context.
Can a blood test diagnose an ovarian cyst?
No. Blood biomarkers cannot diagnose an ovarian cyst on their own. They provide supplementary data that, when combined with imaging (such as ultrasound) and clinical assessment, helps build a more complete picture of ovarian health.
What does a high CA-125 level mean?
An elevated CA-125 level can be caused by a wide range of conditions, many of which are benign. These include endometriosis, fibroids, pelvic inflammatory disease, menstruation, and pregnancy. A high CA-125 result does not automatically indicate a serious condition and should always be interpreted by a healthcare professional.
How often should I test my ovarian biomarkers?
This depends on your individual risk factors and clinical history. Establishing a baseline is recommended, followed by periodic monitoring — typically annually or biannually for those without specific concerns. Women with elevated results or known risk factors may benefit from more frequent testing as advised by a healthcare professional.
How accurate is the ROMA score for assessing ovarian cyst risks?
The ROMA score is considered one of the more reliable tools for risk stratification because it combines two complementary biomarkers (CA-125 and HE4) with menopausal status. While no screening tool is perfect, the ROMA score has been shown to improve discrimination between lower and higher risk presentations compared to individual biomarker assessment.
Can I get ovarian biomarker testing without a GP referral?
Yes. Private health screening clinics in London offer ovarian biomarker blood testing without requiring a GP referral. This can be a convenient option for women who wish to access testing quickly and on their own terms.
Is ovarian biomarker testing suitable for all ages?
Ovarian biomarker testing can be relevant for women across a wide age range, though it is most commonly considered for those of reproductive age and postmenopausal women. The interpretation of results may vary depending on age and menopausal status, which is why the ROMA score incorporates this factor into its algorithm.
What should I do if my biomarker results are elevated?
If any of your biomarker results are elevated, we recommend sharing them with your GP or an appropriate specialist. Elevated results do not automatically indicate a serious condition, but further investigation — which may include repeat testing, additional imaging, or a specialist referral — is advisable to determine the cause and appropriate next steps.
Can menstruation affect my CA-125 results?
Yes. CA-125 levels can be temporarily elevated during menstruation. For this reason, it is often recommended to schedule CA-125 blood testing outside of your menstrual period to minimise the risk of a misleadingly elevated result. HE4, by contrast, is not significantly affected by menstruation.
Are ovarian biomarkers still useful during menopause?
Yes, and in some respects they may be even more informative. In postmenopausal women, CA-125 tends to be less influenced by common benign causes such as menstruation and endometriosis, which can improve its specificity. The ROMA score also adjusts for menopausal status, offering a tailored risk assessment for postmenopausal women.
Taking a Proactive Approach to Ovarian Health
Understanding your ovarian health through evidence-based blood biomarker testing is a positive and proactive step. Whether you are monitoring a known cyst, exploring unexplained symptoms, or simply establishing a baseline for future reference, blood biomarkers such as CA-125, HE4, and the ROMA score can provide valuable, objective data to support your health decisions.
At Health Screening Clinic, we provide private blood testing in London with fast turnaround times and no GP referral required.
About This Article
This content has been developed in line with UK medical editorial standards, drawing upon established clinical guidance and evidence-based health information. All content is reviewed to ensure compliance with GMC advertising guidance, CQC patient communication standards, and ASA regulatory requirements. Our aim is to provide clear, trustworthy, and educational health information that empowers informed decision-making.
Health Screening Clinic provides testing and reporting only. We do not provide medical diagnoses, prescriptions, or treatment. If you have concerns about your results or symptoms, please seek medical advice from appropriate healthcare services. In case of severe symptoms, seek urgent medical care.
Last reviewed: March 2026 | Next review due: March 2027